Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 144

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 144
---

success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product
candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater
clinical data may be available.

More restrictive
government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or
impair the development and commercialization of our current or any of our future product candidates or demand for any products once approved.
Adverse events in ours or others’ clinical trials, even if not ultimately attributable to our product candidates, and the resulting
publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing
or approval of our current or future product candidates, stricter labeling requirements for those product candidates that are approved
and a decrease in demand for any such product candidates, all of which would have a negative impact on our business and operations.

If we encounter difficulties
enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

Identifying and
qualifying patients to participate in our clinical trials is critical to our success. We may encounter difficulties in enrolling patients
in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may
be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials
depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and
efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication,
the proximity of patients to clinical sites and the eligibility criteria for the trial. In addition, enrollment and retention of patients
in clinical trials could be disrupted by man-made or natural disasters, or public health pandemics or epidemics or other business interruptions,
including outbreaks of COVID-19 or other highly transmissible diseases.

Our efforts to
build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials.
Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain
patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result
in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could